Cargando…
Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations
Roflumilast is given as an add-on to inhalation medication in patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis. Animal experiments have documented deleterious effects of roflumilast in bacterial infections, but trials have not reported the risk of bacterial infection...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291283/ https://www.ncbi.nlm.nih.gov/pubmed/32408645 http://dx.doi.org/10.3390/jcm9051442 |
_version_ | 1783545874634244096 |
---|---|
author | Alispahic, Imane Achir Sørensen, Rikke Eklöf, Josefin Sivapalan, Pradeesh Løkke, Anders Seersholm, Niels Vestergaard, Jakob Hedemark Jensen, Jens-Ulrik Stæhr |
author_facet | Alispahic, Imane Achir Sørensen, Rikke Eklöf, Josefin Sivapalan, Pradeesh Løkke, Anders Seersholm, Niels Vestergaard, Jakob Hedemark Jensen, Jens-Ulrik Stæhr |
author_sort | Alispahic, Imane Achir |
collection | PubMed |
description | Roflumilast is given as an add-on to inhalation medication in patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis. Animal experiments have documented deleterious effects of roflumilast in bacterial infections, but trials have not reported the risk of bacterial infections in patients. The objective of this study is to determine, among outpatients with severe COPD in a two-year follow-up period, the risk of hospitalization-requiring pneumonia, severe acute exacerbation in COPD (AECOPD-hosp), and death. Patients with COPD using roflumilast (roflumilast users) were compared to a propensity score-matched COPD control group not using roflumilast (non-roflumilast users). Roflumilast users had an increased 2-year risk of hospitalization-requiring pneumonia (HR 1.5, 95% CI 1.3 to 1.8, p-value < 0.0001) compared to controls, and of AECOPD-Hosp (hazard ratio(HR) 1.6, 95%, confidence interval (CI) 1.5 to 1.8, p-value < 0.0001) and. When adding an active comparator (theophylline) as a matching variable, the signal was largely unchanged. In conclusion, roflumilast was associated with an increased number of hospitalizations for pneumonia and for AECOPD. Since trials have not reported risks of bacterial complications and data regarding severe exacerbations in roflumilast users are sparse and diverging, these data are concerning. Trials focused on the risk of pneumonia, AECOPD, and other bacterial infections in roflumilast users are needed urgently. |
format | Online Article Text |
id | pubmed-7291283 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72912832020-06-17 Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations Alispahic, Imane Achir Sørensen, Rikke Eklöf, Josefin Sivapalan, Pradeesh Løkke, Anders Seersholm, Niels Vestergaard, Jakob Hedemark Jensen, Jens-Ulrik Stæhr J Clin Med Article Roflumilast is given as an add-on to inhalation medication in patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis. Animal experiments have documented deleterious effects of roflumilast in bacterial infections, but trials have not reported the risk of bacterial infections in patients. The objective of this study is to determine, among outpatients with severe COPD in a two-year follow-up period, the risk of hospitalization-requiring pneumonia, severe acute exacerbation in COPD (AECOPD-hosp), and death. Patients with COPD using roflumilast (roflumilast users) were compared to a propensity score-matched COPD control group not using roflumilast (non-roflumilast users). Roflumilast users had an increased 2-year risk of hospitalization-requiring pneumonia (HR 1.5, 95% CI 1.3 to 1.8, p-value < 0.0001) compared to controls, and of AECOPD-Hosp (hazard ratio(HR) 1.6, 95%, confidence interval (CI) 1.5 to 1.8, p-value < 0.0001) and. When adding an active comparator (theophylline) as a matching variable, the signal was largely unchanged. In conclusion, roflumilast was associated with an increased number of hospitalizations for pneumonia and for AECOPD. Since trials have not reported risks of bacterial complications and data regarding severe exacerbations in roflumilast users are sparse and diverging, these data are concerning. Trials focused on the risk of pneumonia, AECOPD, and other bacterial infections in roflumilast users are needed urgently. MDPI 2020-05-12 /pmc/articles/PMC7291283/ /pubmed/32408645 http://dx.doi.org/10.3390/jcm9051442 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Alispahic, Imane Achir Sørensen, Rikke Eklöf, Josefin Sivapalan, Pradeesh Løkke, Anders Seersholm, Niels Vestergaard, Jakob Hedemark Jensen, Jens-Ulrik Stæhr Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations |
title | Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations |
title_full | Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations |
title_fullStr | Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations |
title_full_unstemmed | Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations |
title_short | Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations |
title_sort | roflumilast in severely ill patients with chronic obstructive pulmonary disease with frequent exacerbations: risk of pneumonia hospitalization and severe exacerbations |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291283/ https://www.ncbi.nlm.nih.gov/pubmed/32408645 http://dx.doi.org/10.3390/jcm9051442 |
work_keys_str_mv | AT alispahicimaneachir roflumilastinseverelyillpatientswithchronicobstructivepulmonarydiseasewithfrequentexacerbationsriskofpneumoniahospitalizationandsevereexacerbations AT sørensenrikke roflumilastinseverelyillpatientswithchronicobstructivepulmonarydiseasewithfrequentexacerbationsriskofpneumoniahospitalizationandsevereexacerbations AT eklofjosefin roflumilastinseverelyillpatientswithchronicobstructivepulmonarydiseasewithfrequentexacerbationsriskofpneumoniahospitalizationandsevereexacerbations AT sivapalanpradeesh roflumilastinseverelyillpatientswithchronicobstructivepulmonarydiseasewithfrequentexacerbationsriskofpneumoniahospitalizationandsevereexacerbations AT løkkeanders roflumilastinseverelyillpatientswithchronicobstructivepulmonarydiseasewithfrequentexacerbationsriskofpneumoniahospitalizationandsevereexacerbations AT seersholmniels roflumilastinseverelyillpatientswithchronicobstructivepulmonarydiseasewithfrequentexacerbationsriskofpneumoniahospitalizationandsevereexacerbations AT vestergaardjakobhedemark roflumilastinseverelyillpatientswithchronicobstructivepulmonarydiseasewithfrequentexacerbationsriskofpneumoniahospitalizationandsevereexacerbations AT jensenjensulrikstæhr roflumilastinseverelyillpatientswithchronicobstructivepulmonarydiseasewithfrequentexacerbationsriskofpneumoniahospitalizationandsevereexacerbations |